Literature DB >> 3089397

Resolution of dyskinesia and the "on-off" phenomenon in thyrotoxic patients with Parkinson's disease after antithyroid treatment.

T H Caradoc-Davies.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3089397      PMCID： PMC1340780          DOI： 10.1136/bmj.293.6538.38

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  9 in total

1.  Parkinsonism and hyperthyroidism.

Authors:  S Lavy; E S Marks; O Abramsky
Journal:  Eur Neurol       Date:  1974       Impact factor: 1.710

2.  Hyperthyroidism in patients over the age of 60 years. Clinical features in 85 patients.

Authors:  P J Davis; F B Davis
Journal:  Medicine (Baltimore)       Date:  1974-05       Impact factor: 1.889

3.  Use of thyrotropin-releasing hormone in clinical medicine.

Authors:  J M Hershman
Journal:  Med Clin North Am       Date:  1978-03       Impact factor: 5.456

4.  Brief assessment of the mental state in geriatric domiciliary practice. The usefulness of the mental status questionnaire.

Authors:  L A Wilson; W Brass
Journal:  Age Ageing       Date:  1973-05       Impact factor: 10.668

5.  Depression and Parkinson's disease.

Authors:  R Mayeux; J B Williams; Y Stern; L Côté
Journal:  Adv Neurol       Date:  1984

6.  Interaction of thyrotropin-releasing hormone and dopamine on the release of prolactin from the rat anterior pituitary in vitro.

Authors:  M Hill-Samli; R M MacLeod
Journal:  Endocrinology       Date:  1974-10       Impact factor: 4.736

7.  L-DOPA suppression of thyrotropin-releasing hormone response in man.

Authors:  S W Spaulding; G N Burrow; R Donabedian; M van Woert
Journal:  J Clin Endocrinol Metab       Date:  1972-07       Impact factor: 5.958

8.  "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.

Authors:  C D Marsden; J D Parkes
Journal:  Lancet       Date:  1976-02-07       Impact factor: 79.321

9.  Comparison of lipid and androgen levels after conjugated estrogen or depo-medroxyprogesterone acetate treatment in postmenopausal women.

Authors:  R B Barnes; S Roy; R A Lobo
Journal:  Obstet Gynecol       Date:  1985-08       Impact factor: 7.661
  9 in total
  4 in total

1.  Graves' disease presenting as hemiparkinsonism.

Authors:  J S Davies; P K Morrish; M F Scanlon
Journal:  J Endocrinol Invest       Date:  2001-03       Impact factor: 4.256

2.  Ultrasensitive TSH assay and anti-parkinsonian treatment with levodopa.

Authors:  B Vergès; M Giroud; G Vaillant; B Verges-Patois; J M Brun; R Putelat
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-12       Impact factor: 10.154

3.  Thyroid hormone level is associated with motor symptoms in de novo Parkinson's disease.

Authors:  Tadashi Umehara; Hiromasa Matsuno; Chizuko Toyoda; Hisayoshi Oka
Journal:  J Neurol       Date:  2015-05-19       Impact factor: 4.849

4.  Levodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian rats.

Authors:  Ippolita Cantuti-Castelvetri; Ledia F Hernandez; Christine E Keller-McGandy; Lauren R Kett; Alex Landy; Zane R Hollingsworth; Esen Saka; Jill R Crittenden; Eduardo A Nillni; Anne B Young; David G Standaert; Ann M Graybiel
Journal:  PLoS One       Date:  2010-11-10       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.